Insulet 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Insulet reported 3rd quarter revenue of $842 million, up 19.2% year over year on a reported basis and 19.6% on a constant currency basis.
- U.S. Omnipod revenue grew 14.7%, while international Omnipod revenue grew 31.7% on a reported basis and 33% on a constant currency basis.
- The global customer base grew more than 20% year over year; new customer starts grew low single digits in Q3 and low double digits year to date.
- Adjusted gross margin was 74.2%, up 200 basis points, adjusted operating margin was 22%, up 490 basis points, and adjusted EPS was $1.99, up 60% from $1.24.
- Insulet ended the quarter with $584 million in cash and investments and $750 million available under its revolver; year-to-date free cash flow was $212 million.
- The board approved a $1 billion increase in the share repurchase authorization, with $400 million planned for repurchases in Q4, funded with cash on hand.
- Omnipod Discover had been adopted by more than 35,000 users and 5,000 clinicians as of the call; Omnipod 5’s updated algorithm was in full retail across the US.
- Insulet completed enrollment in the Evolve pivotal study for its fully closed-loop system for type 2 diabetes and continued to target a 510(k) submission in 2027.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Insulet Corporation Third Quarter 2026 Earnings Call. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Clare Trachtman, Vice President, Investor Relations.
Please go ahead. Good morning, and welcome to our Third Quarter 2026 Earnings Call.
Joining me today are Ashley McEvoy, President and Chief Executive Officer, and Flavia Pease, Chief Financial Officer. On the call this morning, we will be discussing Insulet's third quarter results, along with our financial outlook for the fourth quarter and full year 2026. With that, let me start our prepared remarks by reminding everyone that certain statements, including comments regarding our financial outlook, the anticipated impact of our strategic actions, the potential impact of various regulatory and operational matters, and the macroeconomic environment on our results of operations, contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially.
In addition, on today's call, non-GAAP financial measures will be used to help investors understand Insulet's ongoing business performance, including adjusted operating income, adjusted EPS, adjusted tax rate, and constant currency revenue, which is revenue growth excluding the effect of foreign exchange. A reconciliation of certain non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation and available in our earnings release issued this morning, both of which are available on our website. Additionally, unless otherwise stated, all financial commentary regarding dollar and percentage changes will be on a year-over-year reported basis, with the exception of revenue growth rates, which will be on a year-over-year constant currency basis. During the Q&A session this morning, Ashley, Flavia, and I will be available to address any questions. Now I'd like to turn the call over to Ashley.
Ashley? Good morning, everyone, and thanks for joining us to discuss our third quarter results.
Our teams delivered a strong quarter with U.S. performance in our guidance range and international performance that exceeded our plans. As we near the end of the year, we've narrowed our total company full-year outlook to the top end of our prior range to reflect this strength. Throughout the quarter, we continued advancing our strategic priorities, strengthening our commercial capabilities and execution, accelerating innovation, and expanding the category by increasing access and building relationships with prescribers. Importantly, we made progress against the type 2 action plans we laid out on our quarter two call. We are pleased with our progress in the quarter, and I want to take a step back and provide some broader perspective. Insulet has a strong leadership position in one of the largest, fastest-growing, and most under-penetrated segments in med tech.
We are actively extending our leadership in automated insulin delivery and are confident that Omnipod will continue winning a leading share of MDI converts to AID, providing the foundation for sustained top-tier growth. We are clear-eyed and confident about Insulet's near and long-term prospects for growth and outsized value creation, factoring in new competitive products entering the market, as well as our own product pipeline. Let's jump into the details, starting with our performance. in the third quarter, we achieved revenue of $842 million, up nearly 20% year-over-year, with approximately 15% growth in the U.S. and 33% growth internationally. Our increased revenue was supported by over 20% growth in our global customer base compared to the prior year period. You may recall that we ended last year with more than 600,000 global customers, and we continue to drive a 20% plus growth rate versus year-ago levels.
This installed base provides a substantial recurring revenue foundation, as well as a growing source of real-world evidence and data. Globally, new customer starts grew low single digits versus the year-ago period, and year-to-date, new customer starts have grown low double digits. The majority of people with diabetes who convert from MDI to AID choose Omnipod, and over 85% of Omnipod new customer starts come from MDI, demonstrating our success growing the category. There continues to be a large delta between CGM and AID use across our markets, despite ADA guidelines recommending AID as a standard of care. We see a significant opportunity to grow the AID market and reduce the burden of diabetes for millions of people worldwide. New customer starts in quarter three were again balanced across type 1 and type 2 globally, with type 2 diabetes patients accounting for over 40% of U.S. starts.
We have not observed an impact from increased GLP-1 use on type 2 new customer starts, and we continue to view GLP-1s as complementary to insulin. We delivered record gross margin and expanded operating margin in the quarter, reflecting Insulet's industry-leading manufacturing capabilities and ongoing productivity improvements. At the same time, we continue to invest in the company's innovation pipeline and commercial capabilities. As I mentioned, we've narrowed our full-year revenue guidance to the top end of our prior range, reflecting third-quarter results and our expectations for continued momentum in the fourth quarter. As we get closer to 2027, we are providing an updated perspective for next year. We expect the pace of innovation across the category to increase next year, including our launch of Omnipod 6, which will accelerate market growth over time.
At the same time, we expect the competitive environment to become more dynamic as new products come on the market. We plan to take a more conservative approach to our 2027 outlook, while we remain highly confident in Insulet's long-term growth opportunities. Flavia will walk through what this means in terms of our full-year 2026 guidance range and our updated perspective for 2027. Before I turn to our strategic priorities, I want to note the share repurchase we announced this morning. The board approved a $1 billion increase in our share repurchase authorization. The company expects to allocate $400 million toward repurchases in quarter four, funded with cash on hand. These plans reflect our confidence in the strength of the Omnipod platform, our robust pipeline, and the company's long-term trajectory. Insulet has the balance sheet and cash flow to facilitate the repurchases while we continue investing in our future.
Now, let me turn to the progress we continue to make against our strategic priorities: strengthening our commercial capabilities and execution, driving innovation, and expanding the category. First, commercial capabilities and execution. We are taking the right actions to build long-term relationships with people with type 1 and type 2 diabetes and the global healthcare providers who care for them. in quarter three, we completed our second U.S. sales force expansion in two years, increasing our footprint by nearly 25% in this latest phase. Our field representatives also completed a new four-month certification program, preparing them to communicate the clinical and real-world value of Omnipod more effectively. in August, we rolled out the company's first new CRM platform in more than a decade to our U.S. sales team. Optimization is ongoing, and we continue to educate our team on how to make the most of these new capabilities.
We expect the new platform to facilitate better targeting, more effective message delivery, faster decision-making, and closer collaboration over time. Specific to type 2 diabetes, we have now put in place the action plan we shared with you all on the quarter two call, and we are pleased with our progress in improving the quality of starts, the onboarding experience, and the first 90 days of the customer journey. We adjusted our sales force compensation so it now adds a customer retention element and refined our approach for deploying samples. We also continued to strengthen our customer care team by adding clinical specialists focused on retention. We have begun to see an improvement in our sampling program and onboarding and saw type 2 retention rates improve modestly in the third quarter. We expect to see the impact of these initiatives continue to build over time.
Consistent with our type 2 action plan, as well as our strategic priority to accelerate innovation that improves outcomes, we completed the full market release of Omnipod Discover in the U.S. in October. Every day, our products make over 100 million automated dosing decisions and process over 850 million data messages, giving us one of the largest real-world diabetes datasets. This data enables Omnipod Discover, our proprietary engagement platform, to deliver personalized insights and decision support to strengthen engagement, outcomes, and customer loyalty for people with diabetes and healthcare providers using Omnipod. During the Omnipod Discover limited market release, we saw stronger retention, increased time in range, and three-quarters of our users reported feeling more confident managing their diabetes. in October, we began onboarding people with diabetes regardless of healthcare professional enrollment, and we have seen very strong engagement.
As of this call, Discover has been adopted by more than 35,000 users and 5,000 clinicians. We are in the early innings of this platform, but believe Omnipod Discover will be another differentiator for Insulet as people seek more connected and self-managed health solutions. Another recent advancement is our new algorithm enhancement, the most significant improvement to Omnipod 5 since its launch, now in full retail across the U.S. The updated algorithm adds a new 100 milligrams per deciliter target and fewer automated delivery restriction alarms, so users stay in automated mode longer. Real-world evidence shows users achieve more time in range without a meaningful increase in lows, reinforcing Omnipod 5's leadership in delivering strong outcomes with a simple, seamless experience. Robust algorithm innovation will continue to be an important focus, with an emphasis on helping more people address their needs in a differentiated manner.
Our expansive real-world diabetes dataset gives us a unique opportunity to continue building upon our industry-leading position while improving outcomes for Omnipod users. We are excited about this flywheel of innovation and patient impact, and what it means for people with diabetes and all our stakeholders. In quarter two, we expanded sensor choice through our U.S. integration with FreeStyle Libre 3 Plus, and as of today, we have extended integration to 10 new markets. The OUS platform for Libre 3 Plus is underway, with U.S. limited market release expected in quarter four, providing access to 450,000 MDI users. Our teams are executing against this opportunity. At the same time, we are advancing our broader innovation roadmap, including Omnipod 6 and Omnipod fully closed-loop for type 2 diabetes. Omnipod six adapts to how you bolus.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
